Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2002

View Archived Issues

New vaccines reported effective against HPV and HSV infections

Fosamprenavir calcium combined with ritonavir safe and effective in HIV-infected patients

New data on the antiviral efficacy and safety of atazanavir in HIV infection

Teriparatide more effective than alendronate in postmenopausal osteoporosis

Antitumor efficacy of EMD-273063 alone or combined with IL-2

More than 30 years after its introduction, an antibiotic comes back as a novel neuroprotective drug

Enfuvirtide a focus of attention at recent HIV congress

Disappointing preliminary data and negative complete response letter for Replagal

Clinical development program begun for pramipexole in restless legs syndrome

FluINsure vaccine challenge trial commences

Novel opioid analgesics prepared and tested at Euroceltique

Psychotropic agents discovered by Sumitomo scientists

Wyeth presents new oxytocin antagonists with potential as tocolytic agents

New immunosuppressant and antitumor compound isolated at Takeda

BMS researchers present novel inhibitors of HIV reverse transcriptase

Orally active C5a receptor antagonist with potential in inflammatory conditions

Potential new kinase inhibitors for potentiating the effects or radio- and/or chemotherapy

Nabi files BLA for use of Nabi-HB in liver transplant patients

Drug pipeline for schizophrenia

GAM product evaluated in phase I trial for diabetic foot ulcers

Phase I findings for AP-5280 support initiation of phase I/II trial

Ortho Biotech licenses bone morphogenetic protein technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
ATNM-400 radioconjugate shows efficacy in resistant breast cancer
BioWorld Science
Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies...